MaxCyte logo

MaxCyte (MXCT) Q4 2024 Annual Earnings

MXCT·Reported March 11, 2025·After market close

MaxCyte reported Q4 2024 revenue of $8.7M, missed analyst consensus of $9.3M by $578.7K. Diluted EPS came in at $-0.10, beat the $-0.12 consensus by $0.02.

Revenue
$8.7Mmissed by $578.7K
Consensus: $9.3M
Diluted EPS
$-0.10beat by $0.02
Consensus: $-0.12
SEC

SEC Filings

Earnings release8-K not filed yet

Financial Snapshot

Trailing eight quarters through Q4 2024

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q4 2024 Earnings FAQ

Common questions about MaxCyte's Q4 2024 earnings report.

MaxCyte (MXCT) reported Q4 2024 earnings on March 11, 2025 after market close.

MaxCyte reported revenue of $8.7M and diluted EPS of $-0.10 for Q4 2024.

Revenue missed the consensus estimate of $9.3M by $578.7K. EPS beat the consensus estimate of $-0.12 by $0.02.

You can read the 10-K periodic report (0001558370-25-002721) directly on SEC EDGAR. The filing index links above go to sec.gov.